solu-medrol 1g powder for injection vial with diluent vial
pfizer australia pty ltd - methylprednisolone sodium succinate, quantity: 1.326 g (equivalent: methylprednisolone, qty 1 g) - injection, powder for - excipient ingredients: monobasic sodium phosphate monohydrate; dibasic sodium phosphate; sodium hydroxide - when oral therapy is not feasible and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, solu-medrol powder for injection is indicated only for intravenous or intramuscular use in the following conditions:,endocrine disorders,? primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance).,? acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogues are used).,? preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful.,? shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected.,? c
mirena 52 mg intrauterine delivery system
bayer limited - levonorgestrel - intrauterine delivery system - 52 milligram(s) - intrauterine contraceptives; plastic iud with progestogen
rocephin for injection 1 gvial (intramuscular)
roche singapore pte. ltd. - ceftriaxone disodium eqv ceftriaxone - injection, powder, for solution - 1 g/vial - ceftriaxone disodium eqv ceftriaxone 1 g/vial
rocephin for injection 1 gvial (intravenous)
roche singapore pte. ltd. - ceftriaxone disodium eqv ceftriaxone - injection, powder, for solution - 1 g/vial - ceftriaxone disodium eqv ceftriaxone 1 g/vial
celepid 10% w/v intravenous fat emulsion
otsuka (phils.) pharmaceutical, inc.; distributor: zyre pharmaceuticals corporation - intravenous fat emulsion - intravenous fat emulsion - 10% w/v
mirena 52 mg intrauterine delivery system
imed healthcare ltd. - levonorgestrel - intrauterine delivery system - 52 milligram(s) - intrauterine contraceptives; plastic iud with progestogen
kanuma sebelipase alfa rce 2 mg/ml injection intravenous infusion vial
alexion pharmaceuticals australasia pty ltd - sebelipase alfa, quantity: 2 mg/ml - injection, intravenous infusion - excipient ingredients: citric acid monohydrate; sodium citrate dihydrate; water for injections; albumin - kanuma (sebelipase alfa rce) is indicated for long-term enzyme replacement therapy (ert) in patients of all ages with lysosomal acid lipase deficiency (lal-d).
precedex ready to use dexmedetomidine hydrochloride 400 micrograms/100 ml injection for intravenous infusion bottle
pfizer australia pty ltd - dexmedetomidine hydrochloride, quantity: 4.72 microgram/ml (equivalent: dexmedetomidine, qty 4 microgram/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections - intensive care unit (icu) sedation: for sedation of initially intubated adult patients during treatment in an intensive care setting. the use of precedex ready to use by continuous infusion in these patients should not exceed 24 hours.,procedural sedation: for sedation of non-intubated adult patients prior to and/or during surgical and other procedures.
precedex ready to use dexmedetomidine hydrochloride 200 micrograms/50 ml injection for intravenous infusion bottle
pfizer australia pty ltd - dexmedetomidine hydrochloride, quantity: 4.72 microgram/ml (equivalent: dexmedetomidine, qty 4 microgram/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections - intensive care unit (icu) sedation: for sedation of initially intubated adult patients during treatment in an intensive care setting. the use of precedex ready to use by continuous infusion in these patients should not exceed 24 hours.,procedural sedation: for sedation of non-intubated adult patients prior to and/or during surgical and other procedures.
precedex ready to use dexmedetomidine hydrochloride 80 micrograms/20 ml injection for intravenous infusion vial
pfizer australia pty ltd - dexmedetomidine hydrochloride, quantity: 4.72 microgram/ml (equivalent: dexmedetomidine, qty 4 microgram/ml) - injection, intravenous infusion - excipient ingredients: sodium chloride; water for injections - intensive care unit (icu) sedation: for sedation of initially intubated adult patients during treatment in an intensive care setting. the use of precedex ready to use by continuous infusion in these patients should not exceed 24 hours.,procedural sedation: for sedation of non-intubated adult patients prior to and/or during surgical and other procedures.